Obesity weight loss medication and treatment: what the labels show
The main obesity weight loss medication options in 2026 are Zepbound, Wegovy (injection, HD dose and pill), Foundayo, Saxenda and Qsymia, each added to diet and activity. Average loss in their pivotal trials ranged from 7.4% to 20.9% of body weight. Treatment for obesity also includes behavioral programs and, at higher BMIs, metabolic surgery.
What it is
Obesity is a chronic disease of excess body fat. In adults the CDC defines it as a body mass index (BMI) of 30 or higher, and severe obesity as a BMI of 40 or higher (CDC NCHS Data Brief 508). BMI is weight in kilograms divided by height in meters squared; you can work yours out with our BMI calculator.
BMI is a screening number, not a full diagnosis. The ADA's 2026 Standards of Care recommend confirming excess fat with a second measure, such as waist circumference, rather than relying on BMI alone (ADA Standards of Care 2026, Section 8).
For prescribing, the line sits lower. Every obesity medicine label covers adults with a BMI of 30 or more, or 27 or more with at least one weight-related condition such as high blood pressure, abnormal cholesterol or sleep apnea (Zepbound and Wegovy labels).
Why it matters
Obesity is common: 40.3% of US adults had it in August 2021 to August 2023, and 9.4% had severe obesity (CDC NCHS Data Brief 508). It raises the risk of type 2 diabetes, high blood pressure, fatty liver disease, sleep apnea and heart disease.
Modest loss changes those risks. The ADA notes that losing 5% to 7% of body weight improves blood sugar and cardiovascular risk factors, and that sustained loss above 10% usually brings larger benefits (ADA Standards of Care 2026, Section 8). That is why guidelines treat obesity as a condition to manage over years, not a one-off diet.
Treatment options
| Option | What it is | Evidence | Best for |
|---|---|---|---|
| Diet, activity and behavioral support | A calorie deficit of about 500 kcal a day, at least 150 minutes of activity a week and structured counseling. It is the base layer under every other option. | Placebo groups that received this counseling lost 2.4% of body weight at 68 weeks in STEP 1 and 3.1% at 72 weeks in SURMOUNT-1 (Wegovy and Zepbound labels). | Everyone with obesity, alone at lower risk or alongside medicine or surgery. |
| GIP/GLP-1 receptor agonist: tirzepatide (Zepbound) | A once-weekly injection that acts on both the GIP and GLP-1 receptors to reduce appetite and food intake. Made by Eli Lilly. | SURMOUNT-1: average loss of 20.9% at the 15 mg dose versus 3.1% with placebo after 72 weeks (Zepbound label). | Adults who meet the BMI criteria and accept a weekly injection; also labeled for moderate to severe sleep apnea with obesity. |
| GLP-1 receptor agonist: semaglutide (Wegovy) | Novo Nordisk's semaglutide, as a weekly injection (2.4 mg, or 7.2 mg as Wegovy HD) or a daily 25 mg pill. | STEP 1: 14.9% vs 2.4% at 68 weeks. 7.2 mg: 18.8% vs 3.9% at 72 weeks. Pill (OASIS 4): 13.6% vs 2.4% at 64 weeks (Wegovy label). | Adults with obesity, including those with established heart disease, where Wegovy is also labeled to cut the risk of heart attack and stroke. |
| Oral small-molecule GLP-1: orforglipron (Foundayo) | A once-daily Eli Lilly tablet, approved 1 April 2026, taken with or without food. It is not a peptide, so it has no fasting rules. | ATTAIN-1: average loss of 11.1% at 17.2 mg versus 2.1% with placebo after 72 weeks (Foundayo label, Trial 1). | Adults who prefer a pill with no timing rules around meals. |
| Older medicines: liraglutide (Saxenda) and phentermine-topiramate (Qsymia) | Saxenda is a daily GLP-1 injection. Qsymia is a daily capsule combining an appetite suppressant with an anticonvulsant. | Saxenda: 7.4% vs 3.0% at 56 weeks (Saxenda label, Study 1). Qsymia top dose: 10.9% vs 1.6% at one year (Qsymia label, Study 1). | People who cannot take or tolerate a weekly GLP-1, or whose coverage favors an older drug. |
| Metabolic and bariatric surgery | Operations such as sleeve gastrectomy or gastric bypass that reduce stomach size and change gut hormones. | ASMBS/IFSO 2022 recommend surgery at BMI 35 or more regardless of other conditions, and suggest considering it at BMI 30 to 34.9 with metabolic disease. | Higher BMIs, or people for whom medicine has not been enough. |
Approved medications
| Medication | Approved for | Key trial |
|---|---|---|
| Zepbound (tirzepatide) weekly injection | Chronic weight management in adults with BMI ≥30, or ≥27 with a weight-related condition; moderate to severe OSA with obesity | SURMOUNT-1: −20.9% (15 mg) vs −3.1% placebo at 72 weeks |
| Wegovy (semaglutide) 2.4 mg weekly injection | Chronic weight management (adults and ages 12+); cutting major CV events in adults with heart disease; MASH with F2–F3 fibrosis | STEP 1: −14.9% vs −2.4% at 68 weeks; SELECT: major CV events 6.5% vs 8.0% |
| Wegovy HD (semaglutide 7.2 mg) weekly injection | Chronic weight management in adults with obesity | Wegovy label Study 8: −18.8% (7.2 mg) vs −15.5% (2.4 mg) vs −3.9% placebo at 72 weeks |
| Wegovy pill (oral semaglutide 25 mg) daily | Chronic weight management in adults; cutting major CV events in adults with heart disease. Approved 22 Dec 2025 | OASIS 4: −13.6% vs −2.4% at 64 weeks |
| Foundayo (orforglipron) daily tablet | Chronic weight management in adults with BMI ≥30, or ≥27 with a weight-related condition. Approved 1 Apr 2026 | ATTAIN-1: −11.1% (17.2 mg) vs −2.1% placebo at 72 weeks |
| Saxenda (liraglutide 3 mg) daily injection | Chronic weight management in adults and ages 12+ | Saxenda label Study 1: −7.4% vs −3.0% at 56 weeks |
| Qsymia (phentermine-topiramate ER) daily capsule | Chronic weight management in adults and ages 12+ | Qsymia label Study 1: −10.9% (15 mg/92 mg) vs −1.6% placebo at one year |
Where GLP-1 medications fit
GLP-1 based medicines are now the first choice in most guidance because they produce the largest average losses with the strongest outcome data. The AACE's 2025 obesity algorithm prefers semaglutide or tirzepatide for people with prediabetes, type 2 diabetes or fatty liver disease, and semaglutide for preventing heart attack and stroke (AACE consensus, 2025). The Endocrine Society frames every obesity medicine as an addition to diet and activity, not a substitute (Endocrine Society, 2015).
Three practical points:
- Check progress at about 3 months. AACE suggests changing strategy if loss is under 5% by then.
- The best dose is not always the top dose. The ADA advises matching dose to benefit and tolerability (ADA 2026, Section 8).
- Stopping usually means regain. See what happens when you stop a GLP-1.
All carry a boxed warning about thyroid C-cell tumors and are not for anyone with a personal or family history of MTC or MEN 2 (Zepbound, Wegovy and Foundayo labels).
When to see a doctor in person
An in-person visit is the right step if you have a BMI of 40 or more and are weighing up surgery, if you are pregnant or planning pregnancy, or if you have had pancreatitis, gallbladder disease or an eating disorder. See someone in person too for unexplained rapid weight gain, swelling in the legs, or loud snoring with daytime sleepiness. Seek emergency care for severe abdominal pain that spreads to the back, which the GLP-1 labels list as a sign of pancreatitis.
How Temi helps
A licensed Temi physician reviews requests for compounded semaglutide or tirzepatide online, with no appointment, in 10 states. Compounded medicines are a separate, non-FDA-approved preparation, not generic Wegovy or Zepbound. The prescription service is $39 per order (usetemi.com/how-it-works, checked 5 Oct 2026). For an FDA-approved pill, a Temi physician can prescribe Foundayo, dispensed by LillyDirect at $149 for 30 days of the starting dose (usetemi.com/medications/foundayo, checked 5 Oct 2026). Temi does not offer surgery or in-person exams.
Frequently asked questions
What is the most effective obesity weight loss medication?
Among FDA-approved options, tirzepatide (Zepbound) had the largest average loss in its pivotal trial: 20.9% of body weight at the 15 mg dose after 72 weeks, against 3.1% with placebo (SURMOUNT-1, Zepbound label). Wegovy HD 7.2 mg averaged 18.8% at 72 weeks. These are averages; some people lose much less, and the right choice also depends on your other conditions, side effects and cost.
What BMI do you need to qualify for weight loss medication?
The FDA labels for Zepbound, Wegovy, Foundayo and Saxenda cover adults with a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related condition such as high blood pressure, type 2 diabetes, abnormal cholesterol or obstructive sleep apnea. Your prescriber confirms eligibility from your measurements and history; our eligibility checker gives a first estimate.
Is obesity medication better than bariatric surgery?
They suit different people and are often combined. Surgery is recommended at a BMI of 35 or more and can be considered at 30 to 34.9 with metabolic disease (ASMBS/IFSO 2022). Medicine avoids an operation but generally needs to be continued long term to keep the weight off. A surgeon or obesity specialist can compare the two for your BMI and health history.
Is compounded semaglutide or tirzepatide the same as Wegovy or Zepbound?
No. Compounded semaglutide and tirzepatide are made by compounding pharmacies and are not FDA-approved. They are not generics of Wegovy or Zepbound, and the trial results for those brands do not transfer to them. A clinician may prescribe a compounded version when an FDA-approved option is not the chosen path. Ask the prescriber which pharmacy makes it and what is in the vial.
Do you have to stay on obesity medication forever?
Many people regain weight after stopping, which is why the labels describe these medicines as long-term weight maintenance rather than a short course. In the Wegovy label's withdrawal study, people moved to placebo after 20 weeks on treatment regained 6.9% of their weight by week 68, while those who stayed on Wegovy lost a further 7.9%. Whether to continue is a decision for you and your prescriber; ask what a maintenance plan looks like.
Which obesity medicines come as a pill?
Three FDA-approved oral options exist in 2026: the Wegovy pill (oral semaglutide 25 mg, approved 22 December 2025), Foundayo (orforglipron, approved 1 April 2026) and Qsymia capsules. The Wegovy pill is taken on an empty stomach with up to 4 ounces of water, then a 30-minute wait before food; Foundayo can be taken with or without food (Wegovy and Foundayo labels). Our GLP-1 comparison sets them side by side.
Sources
- Obesity and Severe Obesity Prevalence in Adults: United States, August 2021–August 2023 (CDC NCHS Data Brief 508) (checked October 5, 2026)
- 8. Obesity and Weight Management for the Prevention and Treatment of Diabetes: Standards of Care in Diabetes—2026 (ADA) (checked October 5, 2026)
- Zepbound (tirzepatide) prescribing information, Eli Lilly (checked October 5, 2026)
- Wegovy (semaglutide) injection and tablets prescribing information, Novo Nordisk (checked October 5, 2026)
- Foundayo (orforglipron) prescribing information, Eli Lilly (checked October 5, 2026)
- Saxenda (liraglutide) prescribing information, Novo Nordisk (checked October 5, 2026)
- Qsymia (phentermine and topiramate ER) prescribing information (checked October 5, 2026)
- AACE Consensus Statement: Algorithm for the Evaluation and Treatment of Adults with Obesity/Adiposity-Based Chronic Disease (2025) (checked October 5, 2026)
- Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline (2015) (checked October 5, 2026)
- 2022 ASMBS and IFSO Indications for Metabolic and Bariatric Surgery (checked October 5, 2026)
- Temi: how it works (compounded GLP-1 prescription service fee) (checked October 5, 2026)
- Temi: Foundayo (orforglipron) (checked October 5, 2026)
Compounded semaglutide and compounded tirzepatide are not FDA-approved generics of the brand-name products. A licensed 503A compounding pharmacy prepares each one for a single prescription.
Get started
Start online, and a licensed physician reviews your request
A short online questionnaire is the first step. No appointments and no insurance needed.
A licensed physician reviews every request. Nothing on this page is a prescription.